Eagle Pharmaceuticals (EGRX): Notes From Management Meetings - RBC

September 21, 2016 7:00 AM EDT
Get Alerts EGRX Hot Sheet
Price: $69.72 +5.35%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 12 | New: 15
Trade EGRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on Eagle Pharmaceuticals (NASDAQ: EGRX) after hosting two days of meetings with management.

Three key points include: 1) the pipeline is led by Ryanodex in EHS and ecstasy/meth

2) there is further "upside" from the bendamustine franchise

3) capital deployment remains a wildcard

The analyst believes EGRX has established a solid underlying cash flow base with upside to come from the pipeline, greater BENDEKA duration, and capital deployment. EPS for 2016-18E increases to $3.51, $4.31 and $5.39 and the price target goes to $80 from $78.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $64.95 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

RBC Capital

Add Your Comment